California Supreme Court Rules Drugmakers Lack Duty to Innovate

The Supreme Court of California ruled Monday that pharmaceutical manufacturers do not have a legal duty to innovate, meaning they cannot be held negligent for failing to develop safer versions of drugs already considered safe. In a 6-1 decision, the court dismissed negligence claims brought by approximately 24,000 patients against Gilead Sciences.

Plaintiffs alleged that Gilead delayed the development and commercialization of tenofovir alafenamide fumarate (TAF), a safer HIV drug, to maximize profits from tenofovir disoproxil fumarate (TDF), which was linked to bone and kidney problems. The ruling reverses a February 2024 appeals court decision, preventing a legal precedent that would require drugmakers to provide safer alternatives more quickly.

Justice Joshua Groban wrote for the majority that imposing such liability would create substantial burdens on pharmaceutical innovation and public health. Justice Kelli Evans dissented from the decision, characterizing the company's conduct as morally blameworthy.